Trial Profile
A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Paclitaxel; Pertuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 17 May 2016 The treatment table has been amended to include 6 arms (for phase1b and IIa) with different regimens.
- 14 Dec 2013 Results from the phase IIa part of the study (n=44) presented at the 36th Annual San Antonio Breast Cancer Symposium.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.